Acta Pharmaceutica, Vol. 59 No. 1, 2009.
Original scientific paper
https://doi.org/10.2478/v10007-009-0008-9
Predkliničke studije [61Cu]ATSM kao PET radiofarmaka za snimanje fibrosarkoma
AMIR R. JALILIAN
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
NIMA ROSTAMPOUR
; Department of Medical Physics, School of Medicine, University of Medical Sciences, Hamadan, Iran
PEJMAN ROWSHANFARZAD
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
KAMALEDDIN SHAFAII
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
MOHSEN KAMALI-DEHGHAN
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
MEHDI AKHLAGHI
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
Abstract
[61Cu]diacetil-bis(N4-metiltiosemikarbazon) ([61Cu]ATSM) dobiven je iz liganda diacetil-bis(N4-metiltiosemikarbazona) (ATSM) pripravljenog u vlastitom laboratoriju i [61Cu]CuCl2 dobivenog iz natZn(p,x)61Cu (180 μA protonskim zračenjem, 22 MeV, 3.2 h). [61Cu]ATSM je čišćen ionskom kromatografijom. Prema HPLC i RTLC radiokemijska čistoća bila je > 98%. [61Cu]ATSM je davan zdravim glodavcima i glodavcima s tumorom tijekom 210 minuta te je praćena biodistribucija. Žrtvovanjem testiranih životinja te snimanjem primijećena je značajna razlika u akumulaciji [61Cu]ATSM u tumorskom tkivu u odnosu na zdravo tkivo. [61Cu]ATSM je pogodan za dijagnostiku hipoksije tumora pozitron emisijskom tomografijom (PET).
Keywords
radiofarmak; bakar-61; [61Cu]ATSM; hipoksija; pozitronska tomografija; fibrosarkom; snimanje
Hrčak ID:
31929
URI
Publication date:
1.3.2009.
Visits: 2.180 *